查詢結果分析
相關文獻
- 治療慢性B型肝炎新選擇:Vemlidy
- Anticoagulation in Acute Ischemic Stroke
- Comparing the Efficacy and Safety of Atorvastatin and Simvastatin in Asians with Elevated Low-Density Lipoprotein-Cholesterol--A Multinational, Multicenter, Double-Blind Study
- Comparative Study of Compliance, Antitussive Efficacy and Tolerability between Detusiv[feb9] Sustained Release Tablet and Medicon-A[feb9] Capsule in the Treatment of Acute Cough
- 從統計角度來判斷藥物臨床試驗所具有之臨床價值
- The Efficacy and Safety of Recombinant Tissue Plasminogen Activator Infusion in Acute Myocardial Infarction
- 精泰來治療男性免疫性不育的療效和安全性
- 臺灣地區異位性皮膚炎患者使用tacrolimus油膏之療效與安全性評估
- CETP Inhibitor的療效與安全性
- 不同定義日劑量的Statins類降血脂藥品於高血壓患者之臨床療效與安全性評估
頁籤選單縮合
題名 | 治療慢性B型肝炎新選擇:Vemlidy=New Choice for the Treatment of Chronic Hepatitis B Infection: Vemlidy |
---|---|
作者 | 李佩樺; 戴慶玲; 林明宗; | 書刊名 | 藥學雜誌 |
卷期 | 35:3=140 2019.09[民108.09] |
頁次 | 頁78-81 |
分類號 | 418.285 |
關鍵詞 | 慢性B型肝炎; 療效; 安全性; Tenofovir; |
語文 | 中文(Chinese) |
中文摘要 | 慢性B型肝炎 (chronic hepatitis B, CHB) 是嚴重的健康問題,並且是慢性肝病, 肝硬化和肝細胞癌的主要原因之一。目前臨床上治療 CHB 藥物有兩種選擇:干擾 素和口服抗病毒類核苷藥物,其中口服貝樂克 (entecavir, ETV) 及惠立妥 (tenofovir disoproxil fumarate, TDF) 具有強力的抗病毒效果之外,產生抗藥性的機率極低,成為 治療 CHB 的第一線藥物。然而近年來,陸續有使用貝樂克及惠立妥治療之病人,造 成腎臟功能退化及增加骨質密度流失的案例報告。因此,對於 CHB 治療的進一步發 展,除了需具有高抗病毒效力之外,也需改善長期使用的安全性和抗藥性。2016年在 美國上市的韋立得 (tenofovir alafenamide fumarate, TAF, Vemlidy) 為此原因而核准,對 此,本文將針對 TAF 治療 CHB 療效及安全性進一步探討。 |
英文摘要 | Chronic hepatitis B (CHB) infection is a serious health problem and one of the main causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC). Currently, there are 2 options for treating CHB: interferons and nucleos(t)ide analogues (NUCs). Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are the first-line monotherapies for CHB because of their high genetic barrier to resistance and effective viral suppression. However, in recent years, patients with long-term use of ETV and TDF have reported cases of nephrotoxicity and reductions in bone mineral density (BMD). Thus, alternative therapies with high antiviral potency and improved long-term safety and tolerability are needed for further advances in CHB treatment. Tenofovir alafenamide fumarate (Vemlidy) is a new drug recently approved in 2016 by U.S. Food and Drug Administration (FDA) for this purpose. In this regard, this article will discuss the efficacy and safety of TAF in the treatment of chronic hepatitis B. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。